

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 June 2001 (28.06.2001)

PCT

(10) International Publication Number
WO 01/46463 A2

(51) International Patent Classification⁷: **C12Q 1/68**

(21) International Application Number: PCT/EP00/12996

(22) International Filing Date:
20 December 2000 (20.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
A 2170/99 22 December 1999 (22.12.1999) AT

(71) Applicant: **BAXTER AKTIENGESELLSCHAFT**
[AT/AT]; Industriestrasse 67, A-1221 Vienna (AT).

(72) Inventors: **ZIMMERMANN, Klaus**; Harlacherweg
2/2/19, A-1220 Vienna (AT). **TURECEK, Peter**; Haupt-
strasse 59g, Weidling, A-3400 Klosterneuburg (AT).
SCHWARZ, Hans-Peter; Schindlergasse 32, A-1180
Vienna (AT). **RIEGER, Manfred**; Dr. Nemecgasse 1/7/6,
A-2230 Gänserndorf (AT).

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,
DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— Without international search report and to be republished
upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS FOR THE PREPARATION AND USE OF INTERNAL STANDARDS FOR NUCLEIC ACID AMPLIFICATION ASSAYS

(57) Abstract: Internal nucleic acid standards for nucleic acid amplification assays are provided. Specifically, internal nucleic acid standards are provided that are prepared using non-recombinant DNA technology. These internal nucleic acid standards are generally chemically synthesized and have a minimum size of approximately 90 nucleic acid bases. Also provided are internal nucleic acid standards prepared using non-recombinant DNA techniques that are single stranded nucleic acids.



WO 01/46463 A2

METHODS FOR THE PREPARATION AND USE OF INTERNAL STANDARDS FOR NUCLEIC ACID AMPLIFICATION ASSAYS

FIELD OF THE INVENTION

The present invention relates to a process for the detection and quantification
5 of nucleic acids in a sample by using internal nucleic acid standards. Specifically, the
present invention provides internal controls for nucleic acid amplification assays that
are derived by chemical synthesis not through recombinant DNA technology
techniques. More specifically, the present invention relates to chemically synthesized
single stranded nucleic acid constructs useful as internal controls for nucleic acid
10 amplification assays.

BACKGROUND OF THE INVENTION

The routine determination of nucleic acids in biological samples is of ever-
increasing importance both in research and in the applied pharmaceutical and medical
industry. It is of particular importance that biological samples intended for *in vivo* use
15 be screened for nucleic acids associated with transmissible infectious agents. Many of
these infectious agents are either uncultivable, or extremely difficult to culture.
Moreover, immunoassay based detection techniques often lack the sensitivity require
to detect transmissible infectious agents at extremely low concentrations. Therefore,
nucleic acid amplification assays have become the detection method of choice.

20 Recently, the number of biotechnology derived therapeutics have increased
significantly. Biotechnology derived therapeutics include, but are not limited to
recombinant growth factors, recombinant blood coagulation factors and recombinant
vaccines. These recombinant materials are produced in *in vitro* cell culture bioreactors
using recombinant DNA technology. The World health Organization (WHO) and
25 United States Food and Drug Administration (US FDA) have expressed concern that
residual heterologous DNA (a DNA construct containing DNA from two or more
different species) may pose unknown risks. Therefore, these agencies have set limits
on the amount of heterologous DNA that can be present in a biotechnology derived
therapeutic. The WHO requires that the quantity of heterologous contaminating DNA
30 has to be below 100 pg per dose, whereas the US FDA permits a maximum of 10 pg
of DNA per dose. Consequently, all biotechnology-derived products must be tested
for residual heterologous DNA content using nucleic acid detection techniques.

Moreover, in addition to the need to screen biological specimens and
biotechnology derived therapeutics using DNA detection techniques, the burgeoning

area of genomic and genetic typing has even further increased the demand for rapid, sensitive and specific nucleic acid detection assays.

Classical methods for nucleic acid detection such as membrane capture hybridization assays (dot blots) have a maximum sensitivity of approximately 5 pg of DNA. However, these assays are tedious to perform and are notoriously difficult to accurately quantify. Moreover, dot blots are generally manual methods that are not suited for large-scale screening. Consequently, the polymerase chain reaction (PCR) assay as described generally in United States patent application numbers (USPAN) 4,683,195 and 4,683,202 is the preferred technique. Since the development of the original PCR technique in the 1980's, many new modification and improvements have been developed. These include, but are not limited to, the reverse transcriptase PCR (RT-PCR), the ligase PCR (LCR) and the Taqman® PCR (referred to hereinafter collectively as either PCR or nucleic acid amplification assays).

Nucleic acid amplification assays possess exceptional sensitivity and specificity. However, all nucleic acid amplification assays are limited in that samples derived from biological fluids such as blood or cell lysates often contain impurities that inhibit the amplification reaction and lead to false negative results. In addition, false negative results arise as a result of nucleic acid loss in the extraction process. Moreover, technical errors during sample preparation and nucleic acid extraction may also contribute to false negative results. Therefore, internal amplification controls may be added prior to the amplification reaction, or prior to the extraction or purification of the nucleic acid, to permit the recognition of false negative results prior to reporting.

Internal controls for PCR assays generally consisting of nucleic acid molecules that contain a detectable nucleic acid sequence (standard oligonucleotide) that is different from the nucleic acid the assay is designed to detect (target oligonucleotide).

The standard oligonucleotide is generally flanked by the same primer sequence used to initiate amplification of the target oligonucleotide. When the PCR assay is performed correctly, the standard oligonucleotide will be detected during post amplification analysis. Samples having standard oligonucleotide and target oligonucleotide detected are true positives, samples having only standard oligonucleotide detected are true negatives, samples having only target oligonucleotide detected are false positives and samples having no detectable amplified standard oligonucleotide are false negatives.

Generally, internal standards are made using recombinant DNA techniques that result in a recombinant DNA molecules having the standard oligonucleotide sequence flanked by primers consisting of duplex-DNA. However, standard oligonucleotide preparation using recombinant DNA techniques is a costly, time-consuming process and requires skilled scientists. Tedious internal standard preparation procedures currently being used represent a considerable factor in terms of assay time and cost.

Therefore, there is a need for developing internal standards for nucleic acid amplification assays that can be performed quickly and inexpensively without sacrificing assay specificity or sensitivity.

SUMMARY OF THE INVENTION

The present invention provides novel methods for the preparation of nucleic acid amplification assays that address the aforementioned and other problems associated with presently available techniques. In one embodiment of the present invention a process for the detection and quantification of nucleic acids in a sample is provided that consists of adding a chemically synthesized oligonucleotide with a size of at least 90 bases (pairs) to a sample as an internal standard. The sample is then amplified using methods known to those skilled in the art including, but not limited to PCR.

The desired sequence of the internal standard in accordance with the invention is hereby made available in a simple manner by means of chemical synthesis. Numerous firms already exist that offer the synthesis of such oligonucleotides within an extremely short time and at very efficient costs. Oligonucleotide synthesizers such as the Synthesizer 2000 MWG-Biotech AG, Ebenberg (Germany) are also readily available. The quantification of the oligonucleotides synthesized usually takes place automatically in the synthesizer or it is already provided by the synthesizer system. In addition, this quantification is not interfered by the presence of proteins which can be eliminated only as a result of time-consuming, expensive purification and extraction processes in the case of the recombinant DNA techniques in the prior art.

Surprisingly, the process in accordance with the invention is superbly well suited to large-scale industrial use and to comprehensive medical screening tests as a result of the provision of chemically synthesized oligonucleotides with a length of at least 90 bases pairs (bp) as standards, and it specifically offers advantages relative to biologically prepared samples in the organizational and preparative area.

Neither the occurrence of problems with nonspecific bands nor impediments as a result of the formation of primer-dimers have been found in the case of using chemically synthesized oligonucleotide standards starting from a length of approximately 90 bp. In accordance with the invention, use is preferably made, in particular, of standards of a length of 100 to 400 bp and especially 105 to 200 bp.

The term nucleic acid amplification is to be understood primarily to signify processes that are based on the technology that has been developed by Mullis et al. USPAN 4,683,195 and 4,683,202 such as, but not limited to, polymerase chain reaction (PCR), the reverse transcriptase PCR (RT-PCR) or the ligase PCR (LCR).

The standard nucleic acid should advantageously differ from the nucleic acid that is to be amplified in at least one detectable characteristic. In addition, it should advantageously be capable of amplification with the help of the same primer with which the target nucleic acid is amplified. Standard nucleic acids have proven to be practical when they have a different size (e.g., a different number of bases (b) or base pairs (bp) compared to the nucleic acid that is to be quantified or detected). In addition, the use of an additional restriction cleavage site has proven to be advantageous. Otherwise, it is preferable to make use, as the standard nucleic acid, of a nucleic acid that has the greatest possible similarity to the nucleic acid that is to be quantified or detected in the sample. This applies, in particular, to the GC content, the restriction sites, the sequence, etc. Preferred standards differ from the nucleic acid which is to be detected/quantified by at least 10% or 5 bases (base pairs) in terms of their length; in each case, however, these differences also depend on the quantification system for the amplified nucleic acids (for example, gel electrophoresis or a chromatographic process).

The detection and quantification of the amplified nucleic acids can then be undertaken in ways known to those of ordinary skill in the art such as a fluorescence sensitive nucleic acid detection apparatus (if use is made of fluorescent primers). Examples of such nucleic acid detection apparatus are automatic DNA sequencers with laser-induced fluorescence measurement devices, such as the Gene Scanner[®] 373A from the company Applied Biosystems, or HPLC devices. In the case of these types of apparatus, it is even possible to separate nucleic acid molecules from one another when these molecules differ by only one base pair in terms of their length. Such types of apparatus also permit the processing and analysis of a multitude of samples on a gel (e.g., by means of multiplex PCR).

The internal standard is preferably added to the sample prior to any possible pre-purification or extraction of the nucleic acid from the sample; as a result, false negative results that can arise from errors or losses from such pre-purification can be detected. Routine testing with use being made of 2 or more different internal
5 standards (as described in Austrian patent specification number 401,062), which can also be used at different concentrations, can also be established simply and, in particular, inexpensively via the system in accordance with the invention.

Viral nucleic acids are, preferably, detected or quantified in accordance with the invention, especially those in samples that have been taken from body fluids or
10 that serve as the starting product for medical preparations that are to be administered to humans. Typical clinical samples that are frequently tested using nucleic acid amplification assays include, but are not limited to blood, spinal fluid, semen, saliva and tears. Other samples may include, but are not limited to cell culture fluids, recombinant cells, and animal tissue and plant tissue.

The methodology in accordance with the invention has proven valuable especially in the case of viral nucleic acids that can otherwise be made available only via recombinant manipulation and cultivation of the standard. Preferred viruses which can be detected or quantified in accordance with the techniques of this invention are
15 Transfusion-Transmitted Virus (TTV), human parvoviruses, especially parvovirus B19, hepatitis viruses, especially HAV, HBV and HCV, or retroviruses such as the
20 human immunodeficiency virus (HIV).

Parvovirus B19 causes a disease in children, which usually proceeds in a mild fashion, namely infectious erythema. In immunocompromised persons, however, it can lead to erythema infectiosum and transient aplastic crisis in patients with
25 hemolytic anemia, fetal death, arthritis and chronic anemia (Anderson: J. Infect. Dis. 161 (1990), pages 603-608). Transfusion-Transmitted Virus is a new DNA virus which was isolated recently in the serum of patients with post-transfusion hepatitis of unknown etiology (Simmonds et al.: Lancet 352 (1998), pages 191-194; Okamoto et al.: Hepatol. Res. 10 (1998), pages 1-16).

The present process is also particularly well suited to the characterization of
30 nucleic acids or nucleic acid contamination from culture fluids, especially in a process such as that which is described in Austrian patent number 401,270 B.

The sample which is to be examined in accordance with the invention in this connection is advantageously derived from recombinant cells, tissue or animals,

whereby the detection of contamination or genotyping represents prime usage areas in particular.

The invention will be elucidated in more detail by means of the following examples as well as by the figures, though it is not to be limited thereto.

5 BRIEF DESCRIPTION OF THE DRAWING

Fig. 1: Single-stage internally controlled PCR (IC-PCR) for detection of Parvovirus B19. A sample containing Parvovirus B19 DNA was extracted, diluted in tenfold steps: 1 and 3.3 μ L of the last two dilutions subjected to IC-PCR using primer pair KK5 SEQ ID NO: 1/KK6 SEQ ID NO: 2 (lanes 2-5). Additionally the same dilutions were mixed with approximately 10 copies internal control B19c SEQ ID NO: 8 and PCR amplified (lanes 6-9). 142 bp: fragment of wild-type Parvovirus B19, 117 bp: fragment of internal control B19c SEQ ID NO: 8. Lane 1: negative control: lane 10: molecular weight marker (*Msp*I digest of pBR322).

Fig. 2: IC-PCR for detection of TTV after co-extraction of samples and internal control. DNA was extracted from 200 μ L plasma of 5 different pools of 32 healthy donors in the presence of approximately 50 copies internal control TTVc SEQ ID NO: 9. 15 μ L of the extracted DNA solution was subjected to PCR using primer pair TTVS1 SEQ ID NO: 3/TTVA1 SEQ ID NO: 4. The PCR product of the internal control at 105 bp (lanes 1 and 3-5) indicated a successful PCR, a missing PCR product (lane 2) an inhibition of the PCR reaction. A PCR product of 286 bp shows a TTV positive sample (lane 1); lane 6: negative control, lane 7: molecular weight marker (*Msp*I digest of pBR322).

Fig. 3: IC-PCR for genotyping of knockout mice. Tail snips were digested and 3 μ L of the crude lysate were subjected to PCR alone or separately with both primer pairs in the presence of approximately 10 copies internal control FVIIIc SEQ ID NO:10. Primers MC18 SEQ ID NO: 5/MC19 SEQ ID NO: 6: lanes 1-6, primers MC18 SEQ ID NO: 5/neoR2 SEQ ID NO: 7: lanes 7-12. PCRs in lanes 2, 4, 8, 10 are performed without and in lanes 3, 5, 7, 9 in the presence of the internal control FVIIIc SEQ ID NO:10. A PCR product of 680 bp is from normal mice, 160 bp from knockout mice, the internal control FVIIIc SEQ ID NO: 10 yielded either 105 bp (MC18/MC19) or 85 bp (MC18/neoR2). Lanes 1-7: respective negative controls, lane 13: molecular weight marker (*Msp*I digest of pBR322).

DETAILED DESCRIPTION OF THE INVENTION

The terms "internal control," "internal standard," "standards nucleic acid" and "standard oligonucleotide" are used interchangeably. All of the aforementioned terms are meant to refer to the novel, chemically synthesized nucleic acid internal nucleic acid amplification assay control of the present invention.

5 Examples:

Example 1: IC-PCR for detection and quantitation of Parvovirus B19 and TTV and genotyping of FVIII knockout mice

The internal controls (designated by a lower case "c" following the target identifier, for example, if the target is HIV, HIVc would designate the internal control nucleic acid) are custom synthesized oligonucleotides of a size of 105 nucleotides for TTVc SEQ ID NO: 9 and FVIIIc SEQ ID NO: 10 and 117 nucleotides for B19c SEQ ID NO:8 (MWG-BIOTECH GmbH, Ebersberg, Germany) containing the respective forward primer sequences and the complementary sequences of the respective reverse primer. The DNA sequence between the primer sequences was randomly chosen (sequences see Table 1).

Extraction of DNA

Parvovirus B19 DNA was extracted from a sample containing B19 virus with the QIAGEN Blood kit (QIAGEN, Hilden, Germany) following the instructions of the supplier and the DNA was finally eluted with 50 μ L H₂O. The indicated amounts of DNA were then subjected to PCR. For TTV, DNA was extracted from 200 μ L citrated plasma of pools of 32 donors from an anonymous cohort of healthy subjects with the same procedure. In addition, prior the extraction, approximately 50 copies of the single-stranded internal control TTVc SEQ ID NO: 9 were added to the plasma pools. Finally 15 μ L aliquots were subjected to PCR.

25 Crude lysates of mouse tail-snips

Pieces of tails approximately 5 mm in length were digested for 5 hours at 55°C in 600 μ L lysis buffer containing 10 mM Tris-HCl, pH 8.3, 2mM MgCl₂, 0.01% Nonidet®P-40 and 200 μ g/mL Proteinase K (Roche, Mannheim, Germany). The enzyme was inactivated for 10 min at 94°C, and 3 μ L of this lysate was subjected directly to PCR.

Polymerase chain reaction

One to three μL of tenfold dilutions of the B19 sample, 15 μL aliquots of the extracted TTV DNA samples or 3 μL of the tail-snip lysates were subjected to a single-stage IC-PCR employing a thermally activated DNA polymerase. IC-PCR was carried out in a total volume of 50 μL containing 1 Unit HotStarTaq™ (QIAGEN) in the respective buffer supplied by the manufacturer, 200 μM of each dNTP and 50 pmol each of primers of the respective primer pairs (SEQ ID NO: 1 and SEQ ID NO: 2 for B19 and SEQ ID NO 3 :SEQ ID NO: 4 for TTV. Internal controls were added to TTV samples already to the extraction procedure, to the B19 samples and to the tail lysates they were added to the indicated reaction tubes prior to PCR. The sequences of all primers and of the internal controls are shown in Table 1. Samples were then overlaid with mineral oil, incubated for 14 min at 94°C and amplified for 45 cycles in a TRIO-Thermoblock (BioMetra, Göttingen, Germany) with the following cycle profile: 30 s at 94°C, 30 s at 55°C, 60 s at 72°C with a final elongation of 72°C for 1 min. The samples were fractionated on a 3.5% low-melting agarose gel stained with ethidium bromide.

RESULTS

It was previously reported that the use of a Taq DNA polymerase inactive at room temperature has a comparable sensitivity and specificity as nested PCR (Zimmermann et al. BioTechniques 24 (1998), page 222-224) which usually detects single copies of specific templates. In order to achieve highest sensitivity and specificity in a single-stage PCR protocol, a thermally activated DNA polymerase is used. To check the sensitivity of the single-stage PCR set-ups, calculated concentrations of the internal controls were endpoint diluted and repeatedly PCR amplified.

The principle of a single-stranded custom synthesized internal control was first checked in a PCR set-up for the detection of single-stranded DNA virus Parvovirus B19. DNA from a sample containing the virus was extracted and then diluted in tenfold steps to an endpoint. Then 1 and 3.3 μL of the last two dilutions were subjected to PCR. The same concentrations of the B19 sample were also mixed with approximately 10 copies internal control B19c SEQ ID NO: 8. This was the lowest amount necessary always leading to PCR amplification products. The samples were PCR amplified with primers KK5 SEQ ID NO: 1/KK6 SEQ ID NO: 2 located in the highly conserved region of B19 from bp 961 to bp 1102 (PVBAOA strain). Fig. 1

shows that the internal control produced a fragment of the expected 117 bp size (lanes 6-9). It should be noted that the lowest concentration of B19 visible without internal control (lane 4) was in this concentration influenced in its intensity but still clearly visible if mixed with an amount of approximately 10 copies B19c SEQ ID NO: 8 (lane 8). To control extraction efficiency the internal control B19c SEQ ID NO:8 is added prior to a DNA extraction procedure.

The detection of TTV was chosen for demonstrating the usefulness of single-stranded oligonucleotides as internal control for a nucleic acid co-extraction procedure. Because TTV is frequently detected by PCR amplification using various PCR methods and primer sets which are all specific for the same region located in the ORF of TTV (Naoumov et al. Lancet 352 (1998), page 195-197; Nishizawa et al. BBRC 241 (1997), page 92-97; Okamoto et al.; Simmonds et al.). A primer set specific for this region (TTVS1 SEQ ID NO:4/TTVA1 SEQ ID NO: 4) is chosen. Due to a recovery of less than 100% during DNA extraction approximately 50 copies of internal control TTVc SEQ ID NO:9 was the smallest possible number to be added prior to the TTV DNA extraction resulting in positive PCR amplification products. The internal control was added to 200 µL plasma consisting of pools of 32 donors, the samples were extracted and then subjected to IC-PCR. An example for typical IC-PCR experiments is shown in Fig. 2 where a TTV positive sample is shown in lane 1 and a missing PCR product of the internal control at lane 2 indicates an inhibition of the PCR. The PCR product of the internal control at 105 bp (lanes 1 and 3-5) indicates a successful PCR.

The examples of Parvovirus B19 and TTV demonstrate that single-stranded oligonucleotides are useful tools for IC-PCR, but it is still unclear if they could be used equally well in PCR set-ups analyzing double-stranded DNA. This PCR is also used for analysis of FVIII knockout mice as an example to check the tissue. The E-17 factor VIII-deficient mouse strain was produced by Bi et al. (Nat. Genet. 10 (1995), page 119-121; Blood 88 (1996), page 3446-3450) by insertion of a neomycin gene into the 3' end of exon 17 of the factor VIII gene. One of the strategies for breeding is the crossbreeding of normal C57BL/6 females with semizygous affected knockout males (Muchitsch et al. Throm.Haem. 82(4) (1999), page 1371-1373).

To determine the zygosity of the offspring, crude lysates of tail snips are routinely genotyped. Especially to ascertain the heterozygosity of X'X females in crude lysates the addition of internal controls prior to PCR proved to be extremely helpful. An oligonucleotide containing the sequence of MC18 SEQ ID NO: 5 at the

5' end and the complimentary sequences of ne2R SEQ ID NO: 7 and MC19 SEQ ID NO: 6 at the 3' end (resulting after PCR in 85 and 105 bp fragments, respectively) was ordered. Thus, this internal control termed FVIIIc SEQ ID NO: 10 could be used both for amplification with either primer pair MC18/neoR2 resulting in a 160 bp fragment from factor VIII gene of knockout mice or for a separate amplification with MC18/MC19 of knockout mice or for a separate amplification with MC18/MC19 yielding a 680 bp fragment from factor VIII gene of normal mice.

Again, for crude lysates the addition of approximately 10 copies FVIIIc SEQ ID NO: 10 prior to PCR were the lowest number necessary always leading to PCR signals. Fig. 3 shows a typical example of a genotyping experiment performed with two chosen samples of X'X females. Both samples were amplified alone or in the presence of the internal controls with either primer pair MC18 SEQ ID NO: 5/MC19 SEQ ID NO: 6 (lanes 1-6) or MC18 SEQ ID NO: 5/neoR2 SEQ ID NO: 7 (lanes 7-12). Sample 1 (lanes 2, 3, 8, 9) showed all expected bands of the specific template and the internal control with both primer pairs whereas sample 2 (lanes 4, 5, 10, 11) containing obviously PCR inhibitors resulted in only faint bands with MC18/neoR2 (lanes 10 and 11) and in no bands with MC18/MC19 (lanes 4 and 5). Only the use of an internal control avoided a false determination of the genotype.

Example 2: Serial testing of TTV according to the present invention with a comparative test to nested PCR and semi-nested PCR

METHODS

Extraction of DNA

Citrated plasma samples were collected from an anonymous cohort of healthy plasma donors. All were HBV, HCV and HIV-1 negative regular donors. DNA was extracted from 200 µL plasma of a pool of 32 donors with the QIAGEN Blood kit (QIAGEN, Hilden, Germany) following the instructions of the supplier. In addition, prior to the extraction procedure, approximately 50 copies of the single-stranded internal control TTVc SEQ ID NO: 9 were added to the plasma pools and the DNA was finally eluted with 50 µL H₂O. The internal control is custom synthesized 105 base oligonucleotide (MWG-BIOTECH GmbH, Ebersberg, Germany) containing the primer sequence of TTVS1 SEQ ID NO: 3 and the complementary sequence of TTVA1 SEQ ID NO: 4.

Polymerase chain reaction

The extracted DNA solution of the plasma pools was divided in 15 µL aliquots and subjected either to nested PCR as described by Simmonds et al., to semi-nested PCR as described by Okamoto et al., (Taq DNA polymerase and 10x buffer from Pharmacia, Uppsala, Sweden), or to single-stage IC-PCR employing a thermally activated DNA polymerase. IC-PCR was carried out in a total volume of 50 µL containing 1 Unit of HotStarTaq™ (QIAGEN) in the respective buffer supplied by the manufacturer, 200 µM of each dNTP and 50 pmol each of forward primer TTVS1 SEQ ID NO: 3 and reverse primer TTVA1 SEQ ID NO:4. The sequence of all primers and of the internal controls are shown in Table 1. Samples were overlaid with mineral oil, incubated for 14 min at 94°C and amplified for 45 cycles in a TRIO-Thermoblock (BioMetra, Göttingen, Germany) with the following cycle profile: 30 s at 94°C, 30 s at 55°C, 60 s at 72°C with a final elongation at 72°C for 1 min. The samples were then fractionated on a 3.5% low-melting agarose gel stained with ethidium bromide. Amplification of a positive sample with primer pairs TTVS1 SEQ ID NO:3-TTVA1 SEQ ID NO: 4 resulted in the expected 286 bp PCR product and of the internal control in a 105 bp band.

RESULTS

In order to achieve the highest sensitivity and specificity in a single-stage PCR protocol, HotStarTaq™ was used. To determine the sensitivity of this single-stage PCR set-up, the internal control, a simple, custom synthesized 105 base oligonucleotide, was endpoint diluted and repeatedly PCR amplified. Taking into account the Poisson distribution, the sensitivity of our assay was confirmed to be on the single copy level. The IC-PCR is compared with the nested and semi-nested PCR protocols most frequently used at the time for amplification of the same TTV region (Charlton et al. Hepatology 28 (1998), page 839-842; Höhne et al. J. Gen. Virol. 79 (1998), page 2761-2764; Naoumov et al., Nishizawa et al., Okamoto et al., Prescott et al. NEJM 339 (1998), page 776-777; Simmonds et al., Tanaka et al. J. Med. Virol. 56 (1998), page 234-238 and FEBS Letters 437 (1998), 201-206). Considering the previous data (Simmonds et al.), a low prevalence in a European population for this region of TTV was expected and therefore compared 20 different pools consisting of the plasma of 32 donors to obtain more positive samples.

Approximately 50 copies of the internal control (the lowest number necessary always leading to PCR signals) were added to 200 µL plasma, the sample was

extracted and then subjected to IC-PCR, to the nested PCR as described by Simmonds et al. and to the semi-nested PCR as described by Okamoto et al. All samples were independently extracted and subjected to the different PCRs (including positive and negative control) three times. The results are summarized in Table 3. The
5 comparison of the three methods shows a comparable sensitivity and specificity of our method and the method of Simmonds (13/20 vs 11/20 samples positive), whereas in our hands, the PCR set-up as described by Okamoto et al. did not work. From 60 IC-PCRs two reactions were inhibited once (samples 1 and 18) and the two other tests were positive. In contrast to IC-PCR, in these two cases, the conventional PCR would
10 have given false-negative results. Samples 3, 4 and 12 always showed the band of the internal control, but were only positive in two of three PCR experiments, which is probably due to the low copy number of TTV often present in plasma (PCR methods for TTV are obviously at the border of delectability).

Table 1: Sequences of primers and internal controls

Target	Sequence	Oligotype	Primer Sequence	Length of fragment
Parvo B19	KK5	Forward	SEQ ID NO: 1 5'-CCAAGAAACCCCGCATTACC-3'	142 bp
	KK6	Reverse	SEQ ID NO: 2 5'-ACCAGTTTACCATAGTTTGAA-3'	
TTV	TTVS1	Forward	SEQ ID NO 3 5'-ACAGACAGAGGAGAAGGCAAC-3'	286 bp
	TTVA1	Reverse	SEQ ID NO: 4 5'-CTGGCATTTTACCATTTCCTAA-3'	
FVIII knockout	MC-18	Forward	SEQ ID NO: 5 5'-GAGCAAATTCCTGTACTGAC-3'	approx. 680 bp
	MC-19	Reverse	SEQ ID NO: 6 5'-TGCAAGGCCTGGGCTTATTT-3'	(MC18/MC/19)
	neoR2	Reverse	SEQ ID NO: 7 5'-CCGCCCTCCCTTGCGCTAC-3'	approx. 160 bp (MC18/neoR2)
Parvo 19	B19c	Internal Control	SEQ ID NO 8: 5'-GCCAAGAAACCCCGCATTAC CATGTTATGGATAGACTGGC TAAGCAAAGCGCGATCCAAA ACACAAAAGGCTTTGTTCTT TACTCTTTAACTTTGTTCA AACTATGGTAAACTGGT-3'	117 bp
TTV	TTVc	Internal Control	SEQ ID NO: 9 5'-ACAGACAGAGGAGAAGGCAA CATGTTATGGATAGACTGGC TAAGCAAAAAACACAAAAG GCTTTGTTCTTACTCTTTA AACTTTGGAAATGGTAAAAT GCCAG-3'	105 bp
FVIII knockout	FVIIIc	Internal Control	SEQ ID NO: 10 5'-GAGCAAATTCCTGTACTGAC CATGTTATGGATAGACTGGC TAAGCAAAGCGCGATCCAAA	105 bp (MC18/MC/19)

ACACAAGTAGCGCAAGGGAG
GGCGGAAATAAGCCCAGGCC
TTGCA-3'

85 bp
(MC18/ne
oR2)

Table 2: Sequences of primers and internal control

NG059	SEQ ID NO: 11 5'- ACAGACAGAGGAGAAGGCAACATG-3'
NG061	SEQ ID NO: 12 5'- GGCAACATGTTATGGATAGACTGG-3'
NG063	SEQ ID NO: 13 5'- CTGGCATT TTTACCATTTCCAAAGTT-3'
A5430	SEQ ID NO: 14 5'- CAGACAGAGGAGAAGGCAACATG-3'
A5427	SEQ ID NO: 15 5'- TACCAYTTAGCTCTCATTCTWA-3'
A8761	SEQ ID NO: 16 5'- GGMAAYATGYTRTGGATAGACTGG-3'
A5432	SEQ ID NO: 17 5'- CTACCTCCTGGCATT TTTACCA-3'

Table 3: Comparison of three different PCR methods for the detection of TTV

Sample No.	IC-PCR	Nested	Semi-nested
	1 2 3	1 2 3	1 2 3
1	+ + i	+ + -	- - -
2	+ + +	+ + +	- - +
3	+ - +	- - -	- - -
4	- + +	- - -	- - -
5	+ + +	+ + +	- - -
6	+ + +	+ + -	- - -
7	+ + +	+ + +	+ + +
8	- - -	- - -	- - -
9	- - -	- - -	- - -
10	+ + +	+ + +	- + -
11	- i -	- - -	- - -
12	- + +	- + -	- - -
13	+ + +	+ + +	- - -
14	- - -	- - -	- - -
15	- - -	- - -	- - -
16	+ + +	+ + +	- - -
17	- - -	- - -	- - -
18	i + +	- + +	- - -
19	+ + +	+ + +	- - -
20	- - -	- - -	- - -

Each sample (pools of 32 donors) was extracted three times and each extracted solution subjected to the three different PCR set-ups: + = positive, - = negative, i = inhibition of reaction

Reference has been made herein to various patents, printed publications and manufacture instructions for use. Each of the aforementioned references is

5 incorporated herein by reference in their entirety.

What is claimed is:

1. An internal control for a nucleic acid amplification assay comprising:
5 a synthetic nucleic acid wherein said internal control is made using non-recombinant DNA techniques.
2. The internal control of claim 1 wherein said non-recombinant DNA technique is chemical synthesis.
- 10 3. The internal control of claim 1 herein said non-recombinant DNA technique uses a oligonucleotide synthesizer.
4. The internal control of claim 1 wherein said synthetic nucleic acid is single stranded DNA.
5. The internal control of claim 1 wherein said synthetic nucleic acid is single
15 stranded RNA.
6. A method for the detection of nucleic acids in a sample, comprising:
providing a sample;
adding at least one internal nucleic acid standard to the sample;
amplifying nucleic acids present in said sample; and
20 detecting said amplified nucleic acids;
wherein said at least one internal standard is an oligonucleotide synthesized using non-recombinant DNA techniques.
7. The method for the detection of nucleic acids in a sample of claim 6 wherein said method is a quantitative polymerase chain reaction (PCR) assay.
- 25 8. The method for the detection of nucleic acids in a sample of claim 6 wherein said internal nucleic acid standard differs from a target nucleic acid to be detected and wherein said internal standard and said target nucleic acid have at least one detectable difference.

9. The method for the detection of nucleic acids in a sample of claim 6 wherein said nucleic acids are extracted prior to amplifying said nucleic acids in said sample, and whereby said internal nucleic acid standard is added prior to said extraction of said nucleic acids in said sample.
- 5 10. The method for the detection of nucleic acids in a sample of claim 8 wherein said target nucleic acid is viral nucleic acid.
11. The method for the detection of nucleic acids in a sample of claim 10 wherein said viral nucleic acid is selected from the group consisting of transfusion transmissible virus nucleic acid, parvoviruses nucleic acid, hepatitis B virus nucleic acid, hepatitis C virus nucleic acid, and human immunodeficiency virus nucleic acid.
- 10 12. The method for the detection of nucleic acids in a sample of claim 6 wherein said sample is selected from the group consisting of blood, spinal fluid, semen, saliva and tears.
13. The method for the detection of nucleic acids in a sample of claim 6 wherein said sample is cell culture fluid.
- 15 14. The method for the detection of nucleic acids in a sample of claim 6 wherein said sample is selected from the group consisting of recombinant cells, animal tissue and plant tissue.
15. The method for the detection of nucleic acids in a sample of claim 8 wherein said internal nucleic acid standard differs from said target nucleic acid in terms of its length.
- 20 16. The method for the detection of nucleic acids in a sample of claim 15 wherein said internal nucleic acid standard differs from said nucleic acid by at least 10% or 5 bases (base pairs) in terms of its length.

FIG. 1




FIG. 2





FIG. 3



SEQUENCE LISTING

<110> BAXTER AG

Turecek, Peter

Zimmermann, Klaus

Schwarz, Hans-Peter

<120>

<130>

<160> 20

<170> PatentIn Ver. 2.1

<210> 1

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Beschreibung der künstlichen Sequenz:primer

<220>

<223> Description of Artificial Sequence:primer

<400> 1

gccaaagaaac cccgcattac c

21

<210> 2

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Beschreibung der künstlichen Sequenz:primer

<220>

<223> Description of Artificial Sequence:primer

<400> 2

accagtttac catagtttga a

21

<210> 3

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Beschreibung der künstlichen Sequenz:primer

<220>

<223> Description of Artificial Sequence:primer

<400> 3

acagacagag gagaaggcaa c

21

<210> 4

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Beschreibung der künstlichen Sequenz:primer

<220>

<223> Description of Artificial Sequence:primer

<400> 4

ctggcatttt accatttcca a

21

<210> 5

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Beschreibung der künstlichen Sequenz:primer

<220>

<223> Description of Artificial Sequence:primer

<400> 5

gagcaaattc ctgtactgac

20

<210> 6

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 6

tgcaaggcct ggccttattt

20

<210> 7

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 7

ccgccctccc ttgcgctac

19

<210> 8

<211> 14461

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 8

```

arcssrthdt ctnandantc atnnccacds nasamthnvn tnrtanstar cssrthdtct 60
nandantcat nnccacdsna sambysngnt rnanccacds tandardsth rtndtrmnat 120
nnccacdsnb gcasamssvr ncrasngmrt ancbthnrse rchandntha dharmactca 180
andmdcands trynthscnn ctnddamnta mrtancsatt achdnartca rtthdtctnc 240
ntamnatngn ccacdsnmde ascrnngtst swthaargnm brndvdasam sthatartba 300
mndnthcast hatyheckng btchngcayb tandrtnsmr vrtasncss arytdtctmr 360
tsthatardr vdrnthcctr nstnrcmanc wthcrtandn abmtsrscrm rtsthsthwr 420
dhathrgana tnramrrsth atthanttyh trgsentamn atngdnahas tbbwgrdsad 480
mnstrdnrcm bnantrdcts thdtrmnatn sthsdanddr gadmnstrat narstmrstr 540
ngnthratth vrymstcnta mnatnbygdn arndvdadss acctdanadd tnaargaras 600
rthdtctnan dantcatnnc cacdssrrsn tdbythgnty ngvarsndvd asgcsranma 660
srddcbyrcm bnanttchns andasbymdc ascrnngtst snrgardtnc cacymrhsm 720
dnacanbdtc tddwntgvat hcasscamth dgyrthdtrm natnctamn atngdnanam 780
ybyhybrdat nmmbransw hnradactvy abdgncmcrbs arsdwhrthm thdsntrgar 840
ddasbngvry rabscaynrg ardtanttat vnrmatnhwv rthasbnssb tmakmthdsa 900
vaabvathst abshmntncc acdamcatnr cssswhrbyt hsmthdsrmt thcntantca 960
tnanddtctn nccacdnths samsbymans nccacdama tncncasams thathavbnd 1020
rvdrmbgcad sschasbdrc ysatstnctn anmrstthat nhbtthamca tnactnand 1080
adtasngatv rstnschts tsystmsnad dtntnrrncc anarsdrnga mcatnasars 1140
tthssnccac dsnthtract nrcssmrvrt chncarrsr rrrsdrngsa mraratnrth 1200
nccacdtract narasssbth sthsntrnac ntrswchar addrrttha mcatnactn 1260

```

rrrtthtrac tnrrcatnth nccacdhavr vntbadvant agsrrvntng asngatvrst 1320
 snthscnnct nthrcsssth atardscrbd natsandnwh chnccacdan tcatnwasca 1380
 rrdtvathad dtnntrnast andardsart bmhasdnart carnaccrda ncwththnvn 1440
 tnsthatard scrbdthras asnthrmann grrartnwhc hnccacddtc tnandantca 1500
 tnrcssshav bncarrdtwt hsntrnasta ndardsthst andardsara waysrardva 1560
 abgcartsay wththhasmd cnstrctshw vrschntrna standardsa rstsdtratvy 1620
 rarynrtnrc ssswhrbyth ssrbabycas dnartcarby thtmcnsmng rcssrthrra 1680
 ratnschbgc arcsssrthtr aratnstand ardncacds argnraynsv sncthycmrs 1740
 thcnstrctn gntccnstrc tsschasgas mdsthramca tnramvacnn gandthctva 1800
 tnrgansmst hatcntanth scnstrctsa ndthrcatnt hrrsndngs tandardncc 1860
 acdaccrata ntcantandc hckngthrar atnthsstan dardnccacd srrdsbsnty 1920
 aswthsstsh avtbcarrdt anwandndnd ntyrachndv dastandard thstdsrara 1980
 tnthstanda rdsrrsntsa cnsdrabact rntrmstman dcstscayrs crnngtstst 2040
 hatartbcar rdtrtnysca ywhnthstan dardshavtb scdnavryb mannrschas 2100
 ramnthcasc ntamnatnch cksrgntyng thrsntnvt nthrrststs thrbmamakng 2160
 avaabanmrv drcssrthdt ctnandantc atnnccacds nasamwthsb ngmadntrna 2220
 standardsw hrbyshrcs ssanbcarr dtnamannrt hatsmravra bntrmscsta 2280
 ndthatsmrc ntandastrt hrbmaccrd ancwththnv ntsssvdbya rcssrthdtc 2340
 tnandantca tnnccacdsn asamcmrsng thststhrvs nasamthadd tnatastnnt 2400
 rnanccacds tandardtth samcarryng tanamcatnr actnnwhcht hstandarda 2460
 ndrrdatast nthnccacds whchstbant dnthsamars mtansyamda ndthdtctna 2520
 ndantcatnt hamdnccacd swchhschar actrdnthat achmcaysyn thsdgncdtdw 2580
 thasatastb assarssadd dtthsamasa nntrnastan dardthdsrd sncthntrna 2640
 standardna ccdancwth thnvntnshr bymadavaab nasmmannrb ymanschmca 2700
 synthssnmr srmsaradys tthatrthsy nthssschgn ctdswthnan trmyshrttm 2760
 andatvrycn tcstsasars cadgncdtdsy nthsrsscha sramgsynth sssrmwgbtch 2820
 agbnbrggrm anythantca tnthgncdtd synthdsay taksacatma tcaynthsyn 2880
 thsrrtsara dyrvddbyth synthsrsys tmnaddtnth santcatnsn tntrrdbyth 2940
 rsnrctnsw hcanbmnat dnyasarstt mcnsnmngsv rcatnandtr actnrcsssn 3000
 thcasthbgc craratnsta ndardsnthr rartsrrsng ythrcssnac crdancwtht 3060
 hnvntnssrb ywstdtargs candstrasa ndtcmrhnsv mdcascrnng tstsasarst 3120
 thrvsnchmc aysynthsdg nctdswthan gthatastba ssarsassta ndardsandt 3180
 sccayrsadv antagsratv tbgcayrard samsnthrga natnaandra ratvaranth 3240
 rthccrrncr bmswthnnsc cbandsnrmd mntsasarst thrmatnrmr dmrshavbnn 3300
 dnthcassng chmcaysynt hsdgncdtdst andardssta rtngmangt harmatybna 3360
 ccdancwth thnvntnssr rabymadnar tcarstanda rdsangthtb andscaytbt 3420
 htrmccacd amcatnstbn drstdrmayr tsgnyrcsss thatarbasd nthtchngyt 3480
 hathasbndv dbyvnmstas sandgthymr aschanract nrthrvrst ranscrasc 3540
 rrtcrrthga screrthsta ndardnccac dshdadvant agsydrmmth nccacdwhch 3600
 stbamdnata stndtctabc haractrstc naddtntshd advantagsy bcaabamcat 3660
 nwththhths amrmrwthwh chthtargtn ccacdsamdg thcntamnan tthatstbdt 3720
 ctdstandar dnccacdsha vrvntbract cawhntyha vadrntsgad rntnmbrbas 3780
 sbrbasarsb cmardtthnc cacdthatst bantdrdtct dnaddtnths anaddtnars 3840
 trctncavag sthasrvntb advantagst hrwstsrab tmaksasths tandardncc 3900
 acdanccacd thathasthg ratstssbsm artytthncc acdthatstb antdrdtctd 3960
 nthsamthsa snartcartt hgcntntth rstrectnsts thsnetcrrr dstandards 4020
 drrmthncca cdwhchstbd tctdantdb byatastrbass basarsntrm sthrngthna 4080
 chcashwvrt hsdrcnsasd ndnthantca tnsystmrth amdncacds ramgctrhrs 4140

srachrmatg rahcressth dtctnandan tcatnthamd nccacdsan thnbndrtak 4200
 nnawaythat skwnnassch whrbythdtr mnatnrraby taksacwths bngmadance 4260
 acddtctnaa ratsgarsen csnstvncca cddtctnaar atsssmadrs cntrmrsams 4320
 schncacadd tctnaarats aratmatcdn asncrswth srndcdrcsn cmasrmntdv 4380
 csschasgth gnsannrra rmthomanya dbssystemsrh cdvcsnthca sthstysaar 4440
 atstsvnssb tsaratncca cdmcsrmnan thrwhnthsm csdrbynynb asarntmst 4500
 hrngthscht ysaaratsas rmtthrcssn gandanayss amttdsamsn aggbymansm 4560
 tcrthntrna standardsr rabyaddtt hsamrrtany ssbrrcatnr tractnthnc 4620
 cacdrmtsha masarstasn gatvrstsw chcanarsrm rrrsrssrm schrrcatnc 4680
 anbtrdtrtn tstngwthsb ngmadrmrdr ntntnasta ndardsasds crbdnatswh 4740
 chcanasbsd atdrntcncn tratnscana sbstabshds myandnartc arnnsvyvat 4800
 hsystemnacc rdancwthth nvntnvranc cacsarrra bydtctdran tdnaccrdan 4860
 cwththnvnt nscaythns amsthathav bntaknrmdb ydsrthatsr vasthstart 4920
 ngrdctrmdc araratnsth atartbadmn strdthmans thmthdgyna ccdancwth 4980
 thnvntnhas rvnvaabsca ynthcasvra nccacdtha tcanthrsb madavaabny 5040
 varcmbnant manatnandc tvatnthsta ndardrrrdv rsswhchcan bdtctdrant 5100
 dnaccrdanc wththnvntn arttvtrans sntransmtt dvrsarvvrs sscayarvv 5160
 sbhattsvrs sscayhavhb vandhcvrrt rvrssschas thhvsarvv rsbcassads 5220
 aschdrnwh chsayrcdsn amdashnnam ynctsrhythm anmmncmtnt rsnschwrtc 5280
 anadtrythm anctsmant ransntaast ccrssnatnt swthhmytca nmatadatha 5340
 rthrtsandc hrncanmaan drsnncdsa gsttvsanwd navrswchhw assatdrcnt 5400
 ynthsrmatn tswthsttra nssnahatts nknwntgysm mndstaant agskamtah 5460
 atrsagsthr sntrcsssas artcarywst dtthcharac tratnccac dsrnccadc 5520
 ntamnatnrm ctrdsscayn arcssschas thatwhchsd scrbdngatb thsamwhchs 5580
 tbamndnacc rdancwthth nvntnnthsc nctnsadva ntagsydrvd rmrcmbnant 5640
 cstssranma swrbythdt ctnctamna tnrgntyng rsntrmsag arasnartca 5700
 rthnvntnwb cdatdnmrdt abymansthw ngamsaswas bythgrsthg htsnttbmt 5760
 thrtgsngst agccrntna ycntrderrd tctnarvbas amctannga rvbdnawast 5820
 ractddtdnt ndstsandth asttwdtnss bctdtccrsn grmrarkkkk ansaddtnay 5880
 thsamdtsw rmdwtharma tycsntrnac ntrbcander amdansbrag mntwdtyarv 5940
 bbragmntnt rnacntrbca nngatvctr anmcarwght markrmsdgs tbrgccrrdt 6000
 ctnttvatrc tractnsams andntrnacn trdnawastr actdrmasma drntshathy 6060
 dnrsnthrsn carmatycsn trnacntrtt vcthractd dnastnwass bctdtcrsng 6120
 rmrarttvst tvathcrrdc tthntrnacn tratbansan dndcatdasc csscramssn 6180
 gcrdctana nnhbntnher ractnacrrd ctbshwsatt vstvsamana nngatvctr 6240
 anmcarwght markrmsdgs tbrgccrrgn tyngkncktm ctasnsrdg stdandthcr 6300
 dysatwrsbc tdteranrsa ratywthbth rmrarsnthr snarmatyc sntrnacntr 6360
 vcrmrsmcmc ansrmrsmcn ranscrsnan sarrmdwth tandnansnt hrsncthntr 6420
 nacntrvcac rrdctbsrmn rmamcbrmkn cktmethntr nacntrvcyd dthrbmcmcr 6480
 bmcnransrs ctvngatvcr trsanmcarw ghtmarkrms dgstbramsa mccrrdtctn 6540
 andanttatn arvvrband ttvandgnty ngvkncktm mthdsntrna cntrsthnt 6600
 nacntrsarc stmsynthsd gnctdsasnc tdsrttvcn dvcandnctd srbcmwgbtc 6660
 hgmbhbrsbr ggrmanyent anngthrsct vrwardrms ncsandthcm mntarysn 6720
 thrsetvrvr smrthdnas ncbtwnthrm rsncswasra ndmychsn 6780
 tndnaarvbd nawastract drmasamnt anngbvrswt hthagnbdk agnhdngrma 6840
 nywngthnst rctnsthra ndthdnawas naytdwthht hndcatdamn tsdnawrthn 6900
 sbctdterrt tvdnawastr actdrmcetra tdsasdnr srmanannym schrthathy 6960
 sbctswthth samrcdrnad dtnrrthtra ctnarmatyc sthsngstra nddntrnacn 7020

trttvcwrad	ddtthasmas	nayatswrsb	ctdtcrerdy	satsmstasn	scstasarma	7080
tymnnngthw	rdgstdrhrs	atcnysbrc	ntanngmmtr	shchmmngcn	ndtrandgmr	7140
tnaskrchma	nnhmgrmany	thnymwasna	ctvatdrma	tcandthsys	atwassbctd	7200
drctytcrym	raschanrac	tntnddtnst	hbsamatsth	tractdttd	nasamsrtht	7260
asnysatswr	sbctdtasng	stagccrmyn	gathrmayac	tvatddnaym	rasccrwas	7320
arrdtnatta	vmcntanng	tstartatma	gnnthrsctv	brsdbythma	nactrrmach	7380
dntandmach	rmrsthrsc	vmrarsntr	nacntrswra	dddtttvsam	saradyttht	7440
ractnrdrct	thbsamsand	tthtaysats	thywradddt	thndcatdra	ctntbsrrtc	7500
rthsnscsarm	rsandthntr	nacntrsars	hwnntabsam	swrthnvrar	wthmnrancb	7560
atdrmnatca	ndamdrcycs	natrthrmbc	kbntragttn	gngrmanywt	hthwngcyer	7620
satscsatcsa	tcwthanan	atncrmnth	amswractn	atdnawmtng	agrgsgstand	7680
wththdmbrm	drststwasr	vsyrrtdtha	tthsatadna	ymrasnactv	atrmtratr	7740
hasacmarab	snstvyand	scctyasnst	dcrmmrmann	tabtchnsag	whchsaydtc	7800
tssngcsscc	tmatsnrdr	achvhghsts	nstvttyands	cctynasngs	tagcrrtc	7860
hrmayactva	tddnaymras	ssdtchckth	snstvttyths	ngstagerst	scacatdcnc	7920
ntratinsth	trnacntrsw	rndntdtdan	dratdycram	dnachcastw	ascnrmdtha	7980
tthsnstvt	thassayswr	atastnawcy	vthrnccasng	stranddcst	msynthsndt	8040
rnacntrwas	rstchckdna	crstrthdtc	tnsngstran	dddnavrsar	vbdnarmasa	8100
mcntanngth	vrswastrac	tdandthndt	dntndststa	nndntthnan	dthasttwdt	8160
nswrsbctdt	crthsamcnc	ntratinsth	samwrasmdw	tharmatyces	ntrnacntrb	8220
cthsawsthw	stamntncss	aryawaysad	ngtcramcat	nrdctsthsa	mswrcramdw	8280
thrmrskkkk	catdnthhgh	ycnsrvdrn	brmbtbvbba	strangshws	thatthntrn	8340
acntrrdcda	ragmntthct	dbsanstshd	bntdthatth	wstcncntra	tnbvswbwt	8400
ntrnacntra	nwasnthscn	cntratnnnc	dntsnstnsty	btstcaryvs	bmdwthanam	8460
ntarmatyces	bcantcntrt	ractncncyt	hntnacntr	bcsadddrrt	adnatractn	8520
rcdrthdtct	nttvwaschs	nrdmnstrat	ngthsnsssn	gstranddgn	ctdsasnrn	8580
acntrrancc	acdctractn	rcdrsncttv	srntydtctd	bycramcatn	sngvarscrm	8640
thdsandrnr	stswchcara	scctrhsamr	gnecatdnthr	ttvnamvtaa	nctagnshaw	8700
atabbrcagk	amttasmnd	staarmrst	ccrthsrngt	tvsttvasch	sndtarvcry	8760
sshandrng	dnatractna	rmatyecntr	nacntrttvc	wasthsmast	ssbnmbtrba	8820
dddrtrthtt	vdnatractn	rstngnstvc	ramcatnrde	tsthntnac	ntrwasadd	8880
tasmacnsst	ngsdnrsths	amswrtract	dandthnsbc	tdtccranam	rtycaccrm	8940
ntssshwnng	whrattvstv	samsshwna	nandamssng	crrdetthnt	rnacntrata	9000
nndcatsann	hbtnthcrth	crrdetthnt	rnacntrab	ansandndca	tsasccsscr	9060
thamsarvba	ndttvdmnst	ratthatsng	stranddgnc	tdsarstsrc	crbttsstnc	9120
arthydcbsd	aywncrstsa	nayngdbstr	andddnaths	crsassedran	ayssvknckt	9180
mcasanamtc	hckthtssth	actrvdntm	sstranwasr	dcdbybtana	tgntagbdag	9240
bysrtnanm	ycngnntthn	dnthactrvg	nntthstratg	srbrdngsth	crssbrdngn	9300
rmacbmaswt	hhmygsactd	kncktmasc	htschtathr	mhamagtdtr	mnthygstyt	9360
hsrngcrdys	atstasnsar	rtnyngntyds	caytascrta	nthhtrygst	ymasncrdys	9420
atsthaddtn	ntrnacntrs	rrterrvdtb	trmyhangnc	tdcntanngt	hsncmcatth	9480
ndandthcmm	ntarysnscn	randmcatth	ndrstngatr	crnandbrag	mntsrscvty	9540
wasrdrdths	thsntrnacn	trtrmdvced	bsdbthramc	atnwththrr	mrarmcnrrs	9600
tngnabragm	ntrmactrvg	nkncktmerr	asaratamca	tnwthmcmck	ncktmerrras	9660
aratamcatn	wthmcmcydn	gabragmntr	mactrvgnnr	mamcaganas	rcrdysatst	9720
haddtnarma	tycsvcrrtc	rwrthwstnm	brncssarya	waysadngtc	rsgnasgshw	9780
satycaamag	ntyngnmntr	rmdwthtwch	snsamsmasb	thsamswram	danrnrthrsn	9840
cthntrnacn	trswththrr	mrarmcmcan	srmcnranss	amansshwda	ctdbandsth	9900

```

sectmatand thntrnacnt rwthbthrmr arswhrassa manscntann gbvsycrnhb 9960
trsrstdnny antbandswt hmcnransan dandnnband swthmcmcan sandnythsa 10020
nntrnacntr avddaasdtr mnatnthgnt yamsratstn gttvaccrdn gtthrsntnv 10080
ntnwthacma ratvtsttns tdcrandhmn stdcrnthds tractndnac tratdasma 10140
amswrccdr manannymsc hrthathyas madnrsawrh bvhcvandhv ngatvrgard 10200
nrdsnawast ractdrmasm aadnrswtht hagnbdktag nhdngrmany wngthnstre 10260
tnsthsrnad dtnrrttthtr actnrdrar matycsthcn gstranddnt rnacntrttv 10320
cwradddtth asmasandth dnawasnayt dwthhthntr nacntrscst msynthsdba 10380
sgnctdmwgb tchgmbhbrs brggrmanyc ntannghrm rsnccttvsan dthcmmtar 10440
ysncttvaym raschanrac tnthtractd dnastnthas maswasdvdd natsandsbc 10500
tdthrtntsd crasdsrbd bysmmndsta thmnstdcra sdscrdbdyk amttatadna 10560
ymrasandbr rmharmacas aaswdnrtsn gstagccrmy ngathrmaya ctvatddnay 10620
mrascrrwas carrdtnatt avmcntanng htstartatm agnnthrsct vbrsdbythm 10680
anactrrmac hdntandmac hrwardrmrt tvsandrvers rmrttvaths ncarmrsand 10740
thntrnacnt rarshwnnta bsamswrva dwthmnranc batdrmnatc andamdreyc 10800
snatrthrm bckbmtragtt ngngrmanyw ththwngcyc rsatcsatcs atcwthanana 10860
gatnatcrmn thsamswrth nractndnaw mtngagarsg standwthth dmbrmdamca 10920
tnastvsamw thrmrarttv sttvarstdn thctdbccrd ctandthntr nacntrnabb 10980
andrstsnd rtachvthhg hstsnstvy andscctyna sngstagcrr tchtstarta 11040
tmwassdtdt rmnthsnstv tythssngst agcrstthnt rnacntrasm cstmsynths 11100
dbasgnctdw asndntdtda ndrattydca mdtakngnta ccntthssnd strbtnthsn 11160
stvtyrassa ywascnrmdt bnthsngecyv thccrscmar dwththnstd andhmnstde 11220
rrtcsmsrn tysdatthtm ramcatnths amttvrgnch artntahatg yaghhntagn 11280
vragnamvta nshawataka mttarcttt anmagsmmnd statanakat amdvrageand 11340
bsttrscnsd rngthrvsda tasmndsta awrvancnar anatnrthsr gnttvwasct 11400
dandthrrcm arddrntscn sstngthasm adnrstbtan mrstvsamsa rmatycsthcn 11460
trnacntrth wstnmbrncs saryawaysa dngtcrsgna swradddtas mathsamwas 11520
tractdandt hnsbctdtcc rtthnstder asdsrdbdy smmndstaan dtthhmnstde 11580
crasdsrbd bykamttaas amswrndndn tytractdan dsbctdtthd rntcrsnedn 11640
gstvandnga tvcntrthrt msthrstsr smmardntab thcmarsnth thrmthdssh 11700
wsacmarabs nstvtiyands cctyrmthda ndthmthdsm mndsvssams stvwthrasnr 11760
handsthrs tasdsrdbd ykamttaddn twrkrmcrrs twractnsnr nhbtdncsam 11820
sandandtht wthrtstswr stvncntras ttccrnthst wcassthcnv ntnacrwtha 11880
vgvnsngat vrstssamsa ndawaysshw dthbandthn trnacntrbt wrnystvntw 11940
thrcrrmnts whchsrbaby dtthwcynmb rttvtnrnt nasmacrmth dsrttvarbv 12000
syatthbrdr dtctabtyta bsncsrmsa ndntrnacnt rstargtsnc gtyrmrsncn 12060
gthragmntk krwardgcca agaaaccccg cattaccarv bbkkrvrsac cagtttacca 12120
tagtttgaat tvsrwardac agacagagga gaaggcaact tvbttvarvr sctggcattt 12180
taccatttcc aamcrwardg agcaaattcc tgtactgaca rbvkncktmc rvrstgcaag 12240
gectgggctt atttmcmcnr rvrsccgccc tcccttgccg tacarbmcnr arvbcntrna 12300
cntrgccaag aaaccccgca ttaccatggt atggatagac tggctaagca aagcgcgatc 12360
caaaacacaa aaggctttgt tccttactct ttaaactttg ttcaaactat ggtaaactgg 12420
tbttvtvtn trnacntrac agacagagga gaaggcaaca tggtatggat agactggcta 12480
agcaaaaaaa cacaaaaggc tttgttcctt actctttaa ctttggaat ggtaaaatgc 12540
cagbvknckt vcntrnacnt rgagcaaatt cctgtactga ccatgttatg gatagactgg 12600
ctaagcaaag cgcgatccaa aacacaagta gcgcaaggga gggcggaat aagcccaggc 12660
cttgcabmcm cbmcnrtabs ncsmrsand ntrnacntrn gacagacaga ggagaaggca 12720
acatgngggc aacatgttat ggatagactg gngctggcat tttaccattt ccaaagttac 12780

```

```

agacagagga gaaggcaaca tgataccayt tagctctcat tctwaaggma ayatgytrtg 12840
gatagactgg actacctcct ggcattttac catttvsaca gacagaggag aaggcaactt 12900
vactggcatt ttaccatttc caattvcaca gacagaggag aaggcaacat gttatggata 12960
gactgggctaa gcaaaaaaac acaaaaggct ttgttcctta ctctttaaac tttggaaatg 13020
gtaaaatgcc agtabcmars nthrdnrnter mthdsrthdt ctnttvsamn ccrnstdhmn 13080
stdachsams dnrswastra ctdthrtmsa ndachtract dstnsbctdt ththrdnrntc 13140
rstssstvnga tvnhbtrnac tncamsress rthdtctnan dantcatnnc cacadsnasam 13200
cmrsngthst sthrvsnasa mthaddtnat astnntrnan ccacdstand ardtthsamc 13260
arryngtana mcatnractn nwhchthsta ndardandr datastnthn ccacdswhch 13320
stbantdnth samarsmtan syamdandth dtctnandan tcatnthamd nccacdscha 13380
ractrdntha tachmcaysy nthsdgnctd wthasatast bassbasars sadddtthsa 13440
masanntrna standardrc ssnaccrdan cwthcamcha ractrdntha tthnccacds 13500
tandarddrs rmthnccacd whchstbdtc tdrwhchstb antdnrgard tatastndtc 13560
tabcharacter rstcrssna ccrdancwth camrcharac trdnthath nccacdrnth 13620
samsrrdrtr actdrtrcar ryngtthamc atrractnwh rbythntrna standardsr 13680
rabyaddrr tthsrrcatn rtractnth amrcssnacc rdancwthnc amscharacter 13740
rdnthataavr anccacdsdt ctdrantdrc ssnaccrdan cwthcamcha ractrdntha 13800
tthvrancca cddrvsrmitt varvvrssha ttsvrssrth hvrsrccsna ccrdancwth 13860
ncamschara ctrdnthatt hsamhasbnt aknrmabdyd rccsnaccrd ancwthncam 13920
scharacterd nthatthsam hasbntaknr mactrdrcss naccrdancw thncamscha 13980
ractrdntha tthsamsdrv drmrmbnan testssranm asrcssnacc rdancwthnc 14040
amscharacter rdnthatann trnanccacd standardss dthatdrsm thnccacdwh 14100
chstbdtctd rantdntrms tsngthrcss naccrdancw thcamchara ctrdnthata 14160
nntrnancca cdstandard ssdthatdrs rmthnccacd whchstbdtc tdrantdbya 14220
tastrbassb asarsntrms tsngthabst ractarcsss dscrbrdthd tctnandant 14280
catnnccacd snasamwth bngmadntrn astandards andscharac trdnthatas 14340
anntrnasta ndardachmc aysynthsdg nctdwthasa tastbassar ssaddtths 14400
ambnrattra nsatdrmgrm anbythrahm crytransat ncmaywsta vnastntass 14460
a 14461

```

<210> 9

<211> 105

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 9

```

acagacagag gagaaggcaa catgttatgg atagactggc taagcaaaaa aacacaaaag 60
gctttgttcc ttactcttta aactttggaa atggtaaaat gccag 105

```

<210> 10

<211> 105

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 10

gagcaaattc ctgtactgac catgttatgg atagactggc taagcaaagc gcgatccaaa 60
acacaagtag cgcaagggag ggcggaaata agcccaggcc ttgca 105

<210> 11

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 11

acagacagag gagaaggcaa catg 24

<210> 12

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 12

ggcaacatgt tatggataga ctgg 24

<210> 13

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 13

ctggcatttt accatttcca aagtt 25

<210> 14

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 14

cagacagagg agaaggcaac atg

23

<210> 15

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 15

taccayttag ctctcattct wa

22

<210> 16

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 16

ggmaayatgy trtggataga ctgg

24

<210> 17

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 17

ctacctctg gcattttacc a

21

<210> 18

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 18

acagacagag gagaaggcaa c

21

<210> 19

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 19

ctggcatttt accatttcca a

21

<210> 20

<211> 105

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 20

acagacagag gagaaggcaa catgttatgg atagactggc taagcaaaaa aacacaaaag 60

gctttgttcc ttactcttta aactttggaa atggtaaaat gccag

105